Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Capsules × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3 Thoracic 2 Plasma cell 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 CNS 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 241 Paclitaxel 222 Fulvestrant 191 Capecitabine 182 Docetaxel 163 Letrozole 138 pembrolizumab 114 Carboplatin 98 exemestane 97 Gemcitabine 97 Cyclophosphamide 92 palbociclib 85 Anastrozole 82 pertuzumab 77 Lapatinib 73 Bevacizumab 71 ribociclib 67 130-nm albumin-bound paclitaxel 66 eribulin 58 abemaciclib 58 Doxorubicin 55 Vinorelbine 51 Ado-Trastuzumab Emtansine 47 Injections 45 Tamoxifen 44 Everolimus 44 Albumin-Bound Paclitaxel 44 atezolizumab 35 trastuzumab deruxtecan 34 Nivolumab 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262935 2023-10-19

TULIP

Byondis B.V.

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡